Triple Diabetes Pill Outperformed Two-Drug Therapy in Indian Phase III Trial

A single tablet combining three diabetes drugs delivered significantly better blood sugar control than the standard two-drug regimen in a phase III trial of Indian patients with type 2 diabetes, according to results published in Advances in Therapy. The fixed-dose combination of dapagliflozin, glimepiride, and immediate-release metformin cut glycated hemoglobin (HbA1c) by more than two percentage points over 16 weeks, outperforming co-administered glimepiride and metformin on both the primary endpoint and the proportion of patients reaching treatment targets, with no hypoglycemia events reported in the study.

The randomized, open-label, four-arm trial enrolled 536 adults aged 18 to 65 years with type 2 diabetes whose HbA1c levels were between 8.0% and 11.0% despite stable treatment with glimepiride 2 mg and metformin 1000 to 2000 mg daily, alongside diet and exercise. Participants were recruited at 21 sites across India and randomized in equal proportions to one of four twice-daily regimens. Two test arms received the investigational triple fixed-dose combination tablet containing dapagliflozin 5 mg, glimepiride 1 mg, and either metformin 500 mg or 1000 mg, while the two comparator arms received co-administration of glimepiride 1 mg with metformin 500 mg or 1000 mg. The trial was registered with the Clinical Trials Registry India under CTRI/2022/06/043249.

The study design mirrored real-world treatment decisions. During a two-week run-in period, patients previously taking glimepiride 2 mg with metformin 1000 mg were transitioned to glimepiride 1 mg with metformin 500 mg twice daily, while those on higher metformin doses moved to glimepiride 1 mg with metformin 1000 mg twice daily. After randomization, the doses of metformin and glimepiride remained unchanged in the test arms, meaning the only pharmacological difference was the addition of dapagliflozin 5 mg, delivered in a single tablet rather than separate pills. The primary endpoint was the mean change in HbA1c from baseline to the end of week 16, with secondary endpoints covering fasting and postprandial glucose, the proportion of patients achieving HbA1c below 7.0%, body weight, and rescue medication use at weeks 12, 16, and 28.

The results at week 16 showed a clear separation between the triple-therapy and dual-therapy arms. The least-squares mean HbA1c reduction was 2.17% in the lower-dose test arm versus 1.64% in its comparator, a difference that was statistically significant, and 2.25% in the higher-dose test arm versus 1.72% in its comparator, also significant. The reported p values were 0.0005 for the first comparison and below 0.0001 for the second, with 95% confidence intervals for the least-squares mean differences of −0.83 to −0.24 and −0.74 to −0.33, respectively. Baseline HbA1c averaged approximately 9% in all arms, so the reductions represented a substantial share of the excess glycemic burden in this population.

Secondary outcomes reinforced the primary finding. By week 16, 70.68% of patients in the lower-dose test arm had reached HbA1c below 7.0% compared with 46.62% in the corresponding comparator arm, a difference significant at p = 0.0002. In the higher-dose comparison, 78.36% versus 53.38% achieved the target, significant at p < 0.0001. Fasting and postprandial blood glucose declined significantly from baseline in every arm, and the higher-dose triple regimen produced significantly greater reductions in both measures than its comparator at week 16, while the lower-dose comparison was comparable between arms. Body weight changes were small and similar across arms, with mean reductions of roughly half a kilogram at week 16, which the investigators attributed in part to the relatively low baseline body weight of about 68 kg in the study population. No patient required rescue medication during the primary treatment period.

Patients who remained above the HbA1c target at week 16 entered an up-titration phase lasting until week 28, during which the glimepiride dose was increased to 2 mg while all other components stayed the same. In total, 198 of the 530 patients who completed the primary treatment period entered this phase: 39 in the lower-dose test arm, 69 in its comparator, 28 in the higher-dose test arm, and 62 in its comparator. Notably, fewer patients in the triple-therapy arms needed up-titration, which the authors interpreted as a direct consequence of the superior week-16 glycemic control. During the up-titration period, HbA1c, fasting glucose, and postprandial glucose all declined significantly in all four arms, but the reductions were comparable between each test arm and its comparator, and the proportions achieving HbA1c below 7.0% at week 28 were likewise comparable between the paired arms.

The safety findings were a central part of the trial’s message. During the primary treatment period, 32 treatment-emergent adverse events occurred in 26 patients, representing 4.86% of the safety population, with similar incidence across all four groups: 2.99% in the lower-dose test arm, 4.51% in its comparator, 5.22% in the higher-dose test arm, and 6.72% in its comparator. The most commonly reported events were pyrexia, vomiting, and headache. Twenty-four events were mild and eight moderate, all judged unlikely to be related to the study medication, and all resolved. No serious, severe, or life-threatening adverse events were reported, and no hypoglycemia events occurred at any point in the study, a notable finding given that glimepiride, a sulfonylurea, carries an intrinsic risk of low blood sugar. Changes in the liver enzymes AST and ALT and in serum creatinine from baseline to week 16 were minimal and comparable between the fixed-dose combination and its corresponding comparator arms, with similar findings at week 28.

The mechanistic rationale for the combination rests on complementary modes of action. Metformin reduces hepatic glucose production and improves insulin sensitivity, glimepiride stimulates insulin secretion from pancreatic beta cells, and dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, lowers glucose through insulin-independent glycosuria, with associated weight reduction and potential cardiorenal protection. The authors note that combining agents targeting different pathophysiological defects is a recognized strategy in type 2 diabetes, and that international and Indian guidelines, including those from the American Diabetes Association, the Indian Council of Medical Research, and the Research Society for the Study of Diabetes in India, recommend dual or triple therapy when metformin monotherapy fails to achieve adequate control. The trial’s context is also epidemiological: India has the second-highest type 2 diabetes burden after China, with around 101 million affected individuals and another 136 million classified as prediabetic, and national diabetes-related healthcare expenditure is projected to rise from USD 9.80 billion in 2024 to USD 15.30 billion by 2050.

The investigators frame the fixed-dose combination as addressing a practical barrier as much as a pharmacological one. Treatment adherence declines as the number of medications increases, and prior work cited in the paper found that every 10% increase in oral antidiabetic drug adherence was associated with a 0.1% reduction in HbA1c. By consolidating three agents into one tablet taken twice daily, the combination reduces pill burden relative to co-administered separate tablets, which the authors argue could improve adherence, simplify regimens, and lower costs, considerations they describe as particularly relevant in a developing country such as India. The discussion also situates the results against earlier trials: a phase 3 study by Matthaei and colleagues showed that adding dapagliflozin to metformin and a sulfonylurea produced greater HbA1c reduction than placebo at 24 weeks, and a phase 3 study by Sahay and colleagues reported significant HbA1c reduction with a dapagliflozin, glimepiride, and metformin extended-release triple combination compared with a dual fixed-dose combination. The authors state that the current study demonstrated greater HbA1c reduction and a higher proportion of patients achieving HbA1c below 7% at week 16 than these previously published studies.

The trial has limitations that shape how the findings should be read. It was conducted exclusively in India, so population-specific factors including ethnicity, lifestyle, genetics, and environment may limit generalizability to other populations. The open-label design is a further constraint, although the authors point out that the primary and secondary endpoints were objective laboratory-based measures, and randomization with an active comparator minimized allocation bias. The 28-week duration may not capture sustained therapeutic effect or long-term safety, the number of patients entering the second period was relatively small, and patients with diabetic complications were excluded from enrollment. The authors call for longer prospective studies with larger samples, real-world evidence, future assessment of lipid effects, and inclusion of patients with diabetic complications. Within those boundaries, the trial establishes that adding dapagliflozin 5 mg to unchanged glimepiride and metformin, delivered as a single immediate-release tablet, produced superior HbA1c reduction and higher target-achievement rates at 16 weeks than the two-drug regimen alone in Indian patients who remained inadequately controlled on dual therapy, with a safety profile in which no hypoglycemia events and no serious adverse events were recorded.

Subject of Research: Efficacy and safety of a dapagliflozin, glimepiride, and metformin fixed-dose combination tablet in Indian patients with type 2 diabetes

Article Title: Efficacy and Safety of Dapagliflozin, Glimepiride, and Metformin Fixed-Dose Combination Tablet in Type 2 Diabetes: A Phase III Trial

Article References: Kurmi, P., Singh, M. K., Gupta, V., Siddegowda, C., Shukla, J., Gofne, S., Lomte, N., Shendkar, K., Gangwani, D., Kumar, S., Gupta, S., Nagarajaiah, A. G., Bhaskar, A., Kumar, P., Baidya, A., Maiti, A., Gowda, A., Ambaliya, J., Giriappa, B., … Joglekar, S. (2026). Efficacy and Safety of Dapagliflozin, Glimepiride, and Metformin Fixed-Dose Combination Tablet in Type 2 Diabetes: A Phase III Trial. Advances in Therapy. https://doi.org/10.1007/s12325-026-03791-1

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03791-1

Keywords: type 2 diabetes, dapagliflozin, glimepiride, metformin, fixed-dose combination, phase III trial, HbA1c, glycemic control, India, SGLT2 inhibitor, hypoglycemia, clinical trial